Patents by Inventor Ferdinand Hermann Bahlmann

Ferdinand Hermann Bahlmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150309015
    Abstract: Method for determination of compatibility between a donor and a recipient by flow cytometric detection of allo-reactive T cells comprising the following steps: a) addition of a marker to a obtained blood sample from a donor/recipient pair to be analyzed, called labelled sample in the following, wherein the marker is suitable for discrimination of a sample from the recipient; the other blood sample obtained from donor/recipient pair to be analyzed is called in the following non-labelled sample, b) at least one-time dilution of both samples with a first medium, separation of cellular parts of the samples from the liquid phase, c) respective separated reuptake of the cellular parts, in particular in the same volume, of the blood sample residue of the labelled sample, of the blood sample residue of the non-labelled sample in a second medium d) mixing of a part from the non-labelled sample and a part of the labelled sample, in particularly in a ratio of about 1:1 under preservation of a mixture, e) stimulation
    Type: Application
    Filed: December 2, 2013
    Publication date: October 29, 2015
    Inventors: Ferdinand Hermann BAHLMANN, Danilo FLISER, Martina SESTER, Urban SESTER
  • Publication number: 20150301047
    Abstract: A method for recognition of a presence of an infection with CMV in a patient by—determination of a level of CD28neg/CD27neg CD4 T-cells in a whole blood sample obtained from the patient;—comparing the level of CD28neg/CD27neg CD4 T-cells with a level of a control group not infected with CMV; and—defining the presence of the infection with CMV, if the level of CD28neg/CD27neg CD4 T-cells in the patient is significantly higher than the level of CD28neg/CD27neg CD4 T-cells of the control group.
    Type: Application
    Filed: November 25, 2013
    Publication date: October 22, 2015
    Inventors: Ferdinand Hermann Bahlmann, Danilo Fliser, Martina Sester, Urban Sester
  • Publication number: 20130122523
    Abstract: An in-vitro process for the quick determination of the infection status of a Mycobacterium tuberculosis infection from whole blood in terms of active or latent tuberculosis, comprising the steps of: stimulating an antigen-specific T cell that is present in a first sample of whole blood with purified protein derivative (PPD) in the presence of antibodies against CD28, or CD28 and CD49d; processing of PPD by antigen-presenting cells (APC) by incubating for 1.5 h to 2.5 h, especially for 2 h, at 35° C. to 39° C., especially at 37° C., optionally with adding CO2; then adding a secretion inhibitor; effecting an intensive mixing; and another incubation for a period of at least 2.5 h at a temperature of from 35° C. to 39° C.
    Type: Application
    Filed: March 21, 2011
    Publication date: May 16, 2013
    Inventors: Ferdinand Hermann Bahlmann, Danilo Fliser, Martina Sester, Urban Sester
  • Publication number: 20100247452
    Abstract: The present invention relates to the use of erythropoietin for stimulating the physiological mobilization, proliferation and differentiation of endothelial progenitor cells, for stimulating vasculogenesis, for the therapy of diseases associated with a dysfunction of endothelial progenitor cells and for producing pharmaceutical compositions for the treatment of such diseases, and pharmaceutical compositions which comprise erythropoietin and other suitable active ingredients for stimulating endothelial progenitor cells.
    Type: Application
    Filed: April 13, 2010
    Publication date: September 30, 2010
    Applicant: EPOPLUS GMBH & CO. KG
    Inventors: Ferdinand Hermann Bahlmann, Hermann Haller
  • Publication number: 20100247450
    Abstract: The present invention relates to the use of erythropoietin for stimulating the physiological mobilization, proliferation and differentiation of endothelial progenitor cells, for stimulating vasculogenesis, for the therapy of diseases associated with a dysfunction of endothelial progenitor cells and for producing pharmaceutical compositions for the treatment of such diseases, and pharmaceutical compositions which comprise erythropoietin and other suitable active ingredients for stimulating endothelial progenitor cells.
    Type: Application
    Filed: April 13, 2010
    Publication date: September 30, 2010
    Applicant: EPOPLUS GMBH & CO. KG
    Inventors: Ferdinand Hermann Bahlmann, Hermann Haller
  • Publication number: 20100247451
    Abstract: The present invention relates to the use of erythropoietin for stimulating the physiological mobilization, proliferation and differentiation of endothelial progenitor cells, for stimulating vasculogenesis, for the therapy of diseases associated with a dysfunction of endothelial progenitor cells and for producing pharmaceutical compositions for the treatment of such diseases, and pharmaceutical compositions which comprise erythropoietin and other suitable active ingredients for stimulating endothelial progenitor cells.
    Type: Application
    Filed: April 13, 2010
    Publication date: September 30, 2010
    Applicant: EPOPLUS GMBH & CO. KG
    Inventors: Ferdinand Hermann Bahlmann, Hermann Haller
  • Patent number: 7745387
    Abstract: The present invention relates to the use of erythropoietin for stimulating the physiological mobilization, proliferation and differentiation of endothelial progenitor cells, for stimulating vasculogenesis, for the therapy of diseases associated with a dysfunction of endothelial progenitor cells and for producing pharmaceutical compositions for the treatment of such diseases, and pharmaceutical compositions which comprise erythropoietin and other suitable active ingredients for stimulating endothelial progenitor cells.
    Type: Grant
    Filed: July 25, 2003
    Date of Patent: June 29, 2010
    Assignee: Epoplus GmbH & Co. KG
    Inventors: Ferdinand Hermann Bahlmann, Hermann Haller